Inagaki, F.F.; Kato, T.; Furusawa, A.; Okada, R.; Wakiyama, H.; Furumoto, H.; Okuyama, S.; Choyke, P.L.; Kobayashi, H.
Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin. Pharmaceutics 2022, 14, 2037.
https://doi.org/10.3390/pharmaceutics14102037
AMA Style
Inagaki FF, Kato T, Furusawa A, Okada R, Wakiyama H, Furumoto H, Okuyama S, Choyke PL, Kobayashi H.
Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin. Pharmaceutics. 2022; 14(10):2037.
https://doi.org/10.3390/pharmaceutics14102037
Chicago/Turabian Style
Inagaki, Fuyuki F., Takuya Kato, Aki Furusawa, Ryuhei Okada, Hiroaki Wakiyama, Hideyuki Furumoto, Shuhei Okuyama, Peter L. Choyke, and Hisataka Kobayashi.
2022. "Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin" Pharmaceutics 14, no. 10: 2037.
https://doi.org/10.3390/pharmaceutics14102037
APA Style
Inagaki, F. F., Kato, T., Furusawa, A., Okada, R., Wakiyama, H., Furumoto, H., Okuyama, S., Choyke, P. L., & Kobayashi, H.
(2022). Disialoganglioside GD2-Targeted Near-Infrared Photoimmunotherapy (NIR-PIT) in Tumors of Neuroectodermal Origin. Pharmaceutics, 14(10), 2037.
https://doi.org/10.3390/pharmaceutics14102037